Welcome

Welcome to the 2016 San Antonio Breast Cancer Symposium (SABCS), a joint presentation of the Cancer Therapy & Research Center at the University of Texas Health Science Center at San Antonio, Baylor College of Medicine, and the American Association for Cancer Research (AACR).

Welcome also to the new Henry B. Gonzalez Convention Center. We hope that you find the new facilities and symposium layout to be comfortable and conducive to a productive experience while attending SABCS. The new building includes four dining options: the Market Café in the new lobby, a “grab & go” and the Broken Crust Café in the connecting corridor, and El Puente Café in the West Lobby.

Our 2016 program presents much in the way of new knowledge and data which both affect immediate practice and point towards future possibilities for further improving patient care. Areas of particular interest in the clinical domain include endocrine therapy and resistance, advances in targeting not only Her2 but a number of newer pathways, exciting developments in immune therapy, and findings in genetics and genomics which inform prognosis and treatment decisions, plus studies of surgery and radiotherapy in local treatment, and survivorship and economic issues. In addition, there are valuable sessions and presentations on basic science and translational research across a wide range of topics, including uses of circulating tumor cells as well as and circulating tumor DNA and microRNAs; targeting stem cells, DNA repair, and the epigenome; and the cell and molecular biology of metastasis, among others.

The symposium program strives to inform all breast cancer professionals regarding the current frontiers of our knowledge, and to illuminate the way to future progress. We hope not only to share information, but also to encourage development of new and productive collaborations. We also encourage you to take advantage of the many exhibitors and their new products and technologies that could enhance both our research and our patient care.

The symposium takes place over 5 days. Tuesday begins with two career development forums: the first regarding the cultivation of investigator-advocate relations, the second a networking session for young investigators. Continuing the special international sessions which have proven so popular, there is a special session on overcoming obstacles to breast cancer management in low & middle income countries. Educational sessions on a variety of current clinical and basic science topics are also included.

WiFi Access

How to connect in three simple steps:

Step 1: Locate and connect to the network named “SABCS2016”
Step 2: Open your favorite browser
Step 3: When SABCS website loads you are connected

Made possible with support from Lilly Oncology
Welcome continued

translational issues follow. During the subsequent 3 days there are oral presentations of submitted work in 6 general sessions and 6 poster sessions, as well as selected poster discussions. Interspersed with these are 3 invited plenary talks, 5 award lectures, 2 mini-symposia, and clinical and basic science forums and case discussions.

Friday evening brings a new special session “View from the Trenches: What Will You Do On Monday Morning?” in which a distinguished panel will engage in lively discussion of SABCS presentations which might influence patient care in the next week and in the next year.

On Saturday we conclude with a final poster session and then “The Year in Review”, which brings together a panel of distinguished speakers whose succinct reports provide a synthesis of major developments in breast cancer during the past year—one of the most popular parts of the program.

And please take some time to enjoy the lights on the Riverwalk, the award-winning restaurants, and the music and congenial atmosphere that make San Antonio a memorable experience.

Plenary Lecture #1: Management of Metastatic ER+ Breast Cancer

Wednesday, December 7, 8:15 AM, Hall 3
Stephen RD Johnston, MA, MBBS, FRCR, PhD, Royal Marsden Hospital, London, United Kingdom

Recent years have seen much improved understanding of hormone therapy in estrogen-receptor positive (ER+) metastatic breast cancer (BC). Studies in resistance and signaling pathways have led to new combinations therapies that have delivered promising clinical results, but these therapies are often expensive, carry many side effects, or are not readily available to the patients who need them. Single hormone treatment alone may be beneficial to some patients, while others may benefit from targeted endocrine combinations, but determining who may benefit from which treatment remains a challenge.

On Wednesday morning, Stephen Johnston of the Royal Marsden Hospital in London, will discuss how to optimize the use of hormone therapy in estrogen-receptor positive (ER+) metastatic BC. He will review the progress of targeting signaling pathways, such as the mTOR pathway, in combination with aromatase inhibition. Data from the BOLERO-2 trial, which looked at everolimus, an mTOR pathway inhibitor, and exemestane will be reviewed.

New data show significant improvements in the benefits of hormone therapy. Clinical practice guidelines from the National Comprehensive Cancer Network report that median progression-free survival (PFS) with first-line hormone therapy can range from 9-13 months, and 3-4 months with second-line hormonal treatment. According to Dr. Johnston, recent data suggest that a median PFS of >23 months can be achieved with first-line treatment, and 10-11 months with second-line treatment. But how will these findings be integrated into new practice guidelines?

Dr. Johnston, who served on the panel of the American Society of Clinical Oncology, will discuss guidelines that were published in September. These guidelines help develop algorithms for matching and sequencing different treatments to patients who would benefit most from them based on factors such as relapse and resistance.

“It’s a really positive story of how we quite significantly improved the benefits that hormone treatment will give, and it is in the [use of] really crucial first- and second-line treatment of these patients before they need to be committed to chemotherapy,” Dr. Johnston said.

SABCS 2016 Scholarship Recipients

Three programs provided scholarships designed to promote the education and professional development of early-career scientists who are actively pursuing research in breast cancer by facilitating their attendance at SABCS. Scholarships were awarded to graduate students, medical students, residents, and clinical and postdoctoral fellows whose abstracts were accepted for presentation, based on the quality of the abstracts. This year’s awardees are:

SABCS CLINICAL SCHOLARS:
For clinical scientists-in-training who are actively pursuing clinical or clinical/translational research in breast cancer.

Erik Blok, MD MSc
Linnea Langhans, MD
Naisi Huang, MD
Wen Li, PhD
Stephen Luen

SABCS BASIC SCIENCE SCHOLARS:
For laboratory-based investigators-in-training whose work focuses on the biology of breast cancer and preclinical models of its development and progression.

Riley Hampsch, BS
Jonathan Lei
Kevin Shee
Svasti Haricharan, PhD
Xiaotong Li, B.E.

AACR SCHOLAR-IN-TRAINING AWARDS:
Sarah Croessmann
Sarah Hosford, BS
Sarah Croessmann
Nolan Priedigkeit, BS
Daniel Davila-Gonzalez, BA
Katarzyna Jerzak, MD, FRCPC
George Karagiannis, DVM, PhD
Sreeja Sreekumar, PhD
Jessica Finlay-Schultz, PhD
Wen Li, PhD
Maki Tanioka, MD
Joshua Gruber, MD/PhD
Natalia Paez Arango, MD

2016 | SAN ANTONIO BREAST CANCER SYMPOSIUM
Identifying the Right Women for Therapy: A Panel Discussion on Extended Adjuvant Endocrine

Changes in Tumor Biology
Antimitotic Effects to Complex Mechanisms of Action: Beyond targeted and immunotherapies in combination with Prosigna to guiding future clinical decisions.

Metastatic Breast Cancer
Case-Based Discussions for HER2+ Breast Cancer

HR+/HER2- Metastatic Breast Cancer
Clinical Trials of an Innovative, First-in-Class Oral Therapy For the Treatment of a Broad Range of Women With HR+/HER2- Metastatic Breast Cancer

PRODUCT THEATRE SCHEDULE

HALL 2

WEDNESDAY, DECEMBER 7TH

12:15 PM
Case-Based Preoperative Considerations in HER2+ Breast Cancer: A Multidisciplinary Approach
Presented by Genentech

2:00 PM
Clinical Trials of an Innovative, First-in-Class Oral Therapy For the Treatment of a Broad Range of Women With HR+/HER2- Metastatic Breast Cancer
Presented by Pfizer

THURSDAY, DECEMBER 8TH

12:15 PM
Case-Based Discussions for HER2+ Metastatic Breast Cancer
Presented by Genentech

2:00 PM
Present & Future Clinical Applications of the NanoString nCounter Platform: From decentralized prognostic testing of the NanoString nCounter Platform:
Presented by NanoString Technologies

3:30 PM
Mechanisms of Action: Beyond Antimitotic Effects to Complex Changes in Tumor Biology
Presented by Eisai Inc.

FRIDAY, DECEMBER 9TH

12:15 PM
Extended Adjuvant Endocrine Therapy: A Panel Discussion on Balancing Risk vs Benefits and Identifying the Right Women for Prolonged Therapy
Presented by Biotheranostics

CONFERENCE GRANTS

Awards

WILLIAM L. MCGUIRE MEMORIAL LECTURE
Wednesday, December 7, 11:15 AM, Hall 3

The Long and Winding Road: Glancing Back, But Moving Forward
Eric P. Winer, MD - Dana-Farber Cancer Institute • Boston, MA

Dr. Eric Winer, Professor of Medicine at Harvard Medical School and Leader of the Breast Cancer Program at the Dana Farber/Harvard Cancer Center was selected as this year’s William L. McGuire Memorial Lecturer on the basis of his excellence and leadership in clinical research, his outstanding contributions in education and mentorship of young physicians, and his internationally recognized skill as a breast cancer clinician. Dr. Winer is a medical oncologist who spent his early years on the faculty at Duke and moved on to the Dana Farber Cancer Institute 20 years ago to direct the Breast Oncology Program. His important leadership positions include the Board of Directors for the American Society of Clinical Oncology, many roles in the CALGB, now the Alliance for Clinical Trials in Cancer, and his leadership in several treatment guidelines committees including the St. Gallen Breast Cancer Conference. Dr. Winer is widely known for his thoughtful presentations at educational sessions, his ability to interpret and clarify the results of clinical trials, and his mentorship of young trainees and faculty many of whom have become accomplished academicians in their own right. His role as Principle Investigator on the Dana Farber Specialized Program of Research Excellence Grant in Breast Cancer exemplifies his expertise in recognizing important preclinical discoveries and translating them to the clinical care of patients.

Conference Grants

Funding for this conference was made possible (in part) by 1R13CA213939-01 from the National Cancer Institute. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the US Government.

SABCS is supported in part by educational grants from industry. This activity is supported by educational grants and/or educational donations provided by AbbVie, AstraZeneca, Celgene Corporation, Lilly USA, LLC (for further information concerning Lilly grant funding visit www.lillygrantoffice.com), Novartis, Pfizer.

AWARDS

SUSAN G. KOMEN’ BRINKER AWARDS FOR SCIENTIFIC DISTINCTION LECTURES
Wednesday, December 7, 2:15 PM, Hall 3

Established by Komen in 1992, the Brinker Awards for Scientific Distinction recognize the efforts of pioneers in two critically important areas of the fight to end breast cancer. Clinical Research and Basic Science. Advances in both the clinical setting and in our understanding of the underlying mechanisms of breast cancer are essential to combating the disease.

Two leading breast cancer investigators today join the ranks of an esteemed group of scientists who have been recognized for advancing breast cancer research and medicine with the prestigious Brinker Awards – the highest scientific honor awarded by Susan G. Komen, the world’s leading breast cancer organization.

Changing Paradigms in the Local Therapy of Breast Cancer: Making Less More
Monica Morrow, M.D., FACS, chief of the Breast Surgery Service and Anne Burnett Windfohr Chair of Clinical Oncology at Memorial Sloan Kettering Cancer Center and Professor of Surgery at Weill Cornell Medical College, will receive the Brinker Award for Scientific Distinction in Clinical Research.

Dr. Morrow has been a champion of the idea that “more is not necessarily better” when it comes to breast cancer treatments, devoting her career to advancing clinical practice and empowering women to make treatment decisions. She was instrumental in showing that sentinel lymph node dissection is an effective and safe alternative to complete (axillary) lymph node dissection for many women with early metastatic breast cancer. She is held in high regard for her commitment to evidence-based surgery, and has led a number of clinical trials and national committees that have advanced less-invasive surgical treatments and developed standards for breast-conserving surgery which have helped shape the standard of breast cancer care for patients around the world.

Dr. Eric Winer, also Chief Scientific Advisor for Komen, recognized Dr. Morrow’s vital contributions.

Dr. Morrow is a leader in breast cancer surgery and has developed standards for breast-conserving surgery which have helped shape the standard of breast cancer care for patients around the world.

Dr. Morrow has been a champion of the idea that “more is not necessarily better” when it comes to breast cancer treatments, devoting her career to advancing clinical practice and empowering women to make treatment decisions. She was instrumental in showing that sentinel lymph node dissection is an effective and safe alternative to complete (axillary) lymph node dissection for many women with early metastatic breast cancer. She is held in high regard for her commitment to evidence-based surgery, and has led a number of clinical trials and national committees that have advanced less-invasive surgical treatments and developed standards for breast-conserving surgery which have helped shape the standard of breast cancer care for patients around the world.

Dr. Morrow has been a champion of the idea that “more is not necessarily better” when it comes to breast cancer treatments, devoting her career to advancing clinical practice and empowering women to make treatment decisions. She was instrumental in showing that sentinel lymph node dissection is an effective and safe alternative to complete (axillary) lymph node dissection for many women with early metastatic breast cancer. She is held in high regard for her commitment to evidence-based surgery, and has led a number of clinical trials and national committees that have advanced less-invasive surgical treatments and developed standards for breast-conserving surgery which have helped shape the standard of breast cancer care for patients around the world.

Dr. Morrow has been a champion of the idea that “more is not necessarily better” when it comes to breast cancer treatments, devoting her career to advancing clinical practice and empowering women to make treatment decisions. She was instrumental in showing that sentinel lymph node dissection is an effective and safe alternative to complete (axillary) lymph node dissection for many women with early metastatic breast cancer.

Dr. Morrow has been a champion of the idea that “more is not necessarily better” when it comes to breast cancer treatments, devoting her career to advancing clinical practice and empowering women to make treatment decisions. She was instrumental in showing that sentinel lymph node dissection is an effective and safe alternative to complete (axillary) lymph node dissection for many women with early metastatic breast cancer. She is held in high regard for her commitment to evidence-based surgery, and has led a number of clinical trials and national committees that have advanced less-invasive surgical treatments and developed standards for breast-conserving surgery which have helped shape the standard of breast cancer care for patients around the world.

Dr. Morrow has been a champion of the idea that “more is not necessarily better” when it comes to breast cancer treatments, devoting her career to advancing clinical practice and empowering women to make treatment decisions. She was instrumental in showing that sentinel lymph node dissection is an effective and safe alternative to complete (axillary) lymph node dissection for many women with early metastatic breast cancer.

Dr. Morrow has been a champion of the idea that “more is not necessarily better” when it comes to breast cancer treatments, devoting her career to advancing clinical practice and empowering women to make treatment decisions. She was instrumental in showing that sentinel lymph node dissection is an effective and safe alternative to complete (axillary) lymph node dissection for many women with early metastatic breast cancer.

Dr. Morrow has been a champion of the idea that “more is not necessarily better” when it comes to breast cancer treatments, devoting her career to advancing clinical practice and empowering women to make treatment decisions. She was instrumental in showing that sentinel lymph node dissection is an effective and safe alternative to complete (axillary) lymph node dissection for many women with early metastatic breast cancer.

Dr. Morrow has been a champion of the idea that “more is not necessarily better” when it comes to breast cancer treatments, devoting her career to advancing clinical practice and empowering women to make treatment decisions. She was instrumental in showing that sentinel lymph node dissection is an effective and safe alternative to complete (axillary) lymph node dissection for many women with early metastatic breast cancer.

Dr. Morrow has been a champion of the idea that “more is not necessarily better” when it comes to breast cancer treatments, devoting her career to advancing clinical practice and empowering women to make treatment decisions. She was instrumental in showing that sentinel lymph node dissection is an effective and safe alternative to complete (axillary) lymph node dissection for many women with early metastatic breast cancer.

Changing Paradigms in the Local Therapy of Breast Cancer: Making Less More

Breast Cancer Genomics: From the Individual to the Human Population

This year’s Brinker Award for Scientific Distinction in Basic Science will be presented to Charles Perou, Ph.D., the May Goldman Shaw Distinguished Professor of Molecular Oncology and Professor of Genetics and Pathology & Laboratory Medicine at the University of North Carolina School of Medicine and co-program leader of the breast cancer research program and member of the UNC Lineberger Comprehensive Cancer Center.

For nearly two decades, Dr. Perou has worked to decipher genomic information to help inform treatment decision making for breast cancer patients. His contributions to research include the characterization of the diversity of breast tumors, which demonstrated that breast cancers can be classified into at least five molecular subtypes and led to the discovery of the basal-like/triple-negative breast cancer (TNBC) subtype. He and his colleagues were also among the first to discover that the breast cancer subtypes were of prognostic and predictive value, and furthermore to associate specific genetic mutations with specific breast cancer subtypes.

“Dr. Perou has been a giant in the study of breast cancer genomics,” said Komen Chief Scientific Advisor Dr. George Sledge. “From his early work defining breast cancer intrinsic subtypes to his leadership of the Breast Cancer TCGA (The Cancer Genome Atlas) project, his work has changed how we view the biology of the disease and has informed novel therapeutic approaches.”
The SABCS program could not be produced without the members of the Executive Committee, the Program Planning Committee, and the Abstract Review Committee. We thank them for their hard work in making SABCS one of the premier single-site cancer conferences in the world. Almost as soon as the prior year's meeting ends, these individuals work tirelessly all year long to determine the focus of the meeting, line up speakers, coordinate special events, and review thousands of abstracts -- selecting material and designing programs that most accurately represent the cutting edge of breast cancer research. Please refer to your Pocket Program for the names of everyone who helped make this year's event possible.

SABCS gratefully acknowledges Susan G. Komen® for generous support of AACR Outstanding Investigator Award for Breast Cancer Research, and partial support of Educational Sessions.

**Supporters**

We are proud to acknowledge the following for their contributions to and generous support of our program:

**PREMIER**
- AstraZeneca
- Genentech
- Lilly Oncology
- Pfizer

**ANGEL**
- AbbVie
- Genomic Health, Inc.

**PATRON**
- Biotheranostics
- Celgene Corporation
- Eisai, Inc.
- Novartis Oncology

**MAJOR SUPPORTER**
- Myriad Genetic Laboratories, Inc.
- NanoString Technologies
- The Oncologist/Alphamed Press
- TESARO
- Wolters Kluwer

**CONTRIBUTOR**
- Agency, Inc.
- Counsyl
- Dignitana AB
- Heron Therapeutics
- R-Pharm US
- Spectrum Pharmaceuticals, Inc.

**DONOR**
- Amgen
- BioMed Central
- Caris Life Sciences
- Med Fusion
- Medtronic
- Menarini Silicon Biosystems
- Merck & Co., Inc.
- Miraca Life Sciences
- Mitra Biotech
- Paxman Coolers, Ltd.
- Prelude Corporation
- Quest Diagnostics
- Research To Practice
- Sandoz, Inc
- Syndax Pharmaceuticals, Inc.
- Translational Research In Oncology
- Xoft, a subsidiary of iCAD, Inc.
Download the
2016 SAN ANTONIO BREAST CANCER SYMPOSIUM
MOBILE APP

Navigate the event like a pro with the SABCS 2016 mobile app, powered by core-apps.com

WITH THE SABCS 2016 MOBILE APP, YOU CAN:
• Stay organized with up-to-the-minute Exhibitor, Speaker, and Event information
• Sync the app across all of your devices with Multi-Device Sync
• Receive important real-time communications from SABCS
• Build a personalized schedule and bookmark exhibitors
• Take notes and download event handouts and presentations
• Rate the sessions you attend and comment on them, too
• Interactively locate sessions and exhibitors on the Henry B. Gonzalez Convention Center maps
• Visit your bookmarked exhibitors with the Quick List
• Find attendees and connect with your Colleagues through Friends
• Stay in-the-know and join in on social media with #SABCS
• And much, much more!

DOWNLOADING THE APP IS EASY!
SEARCH:
The App Store or Google Play for “SABCS Mobile App”

SCAN:
Also available at: www.core-apps.com/dl/sabcs2016
Questions: support@core-apps.com

Platform Compatibility:
Android v4x+ and iOS v7x+